Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells
Authors
Keywords
-
Journal
MATRIX BIOLOGY
Volume 118, Issue -, Pages 47-68
Publisher
Elsevier BV
Online
2023-03-06
DOI
10.1016/j.matbio.2023.03.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular mechanisms associated with chemoresistance in esophageal cancer
- (2022) Matheus Lohan-Codeço et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers
- (2022) Leonardo Marques da Fonseca et al. GLYCOCONJUGATE JOURNAL
- ABC transporters in breast cancer: their roles in multidrug resistance and beyond
- (2022) Anupama Modi et al. JOURNAL OF DRUG TARGETING
- Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
- (2022) Talha Bin Emran et al. Frontiers in Oncology
- Expression of O-glycosylated oncofetal fibronectin in alternatively activated human macrophages
- (2022) Marcos Andre Rodrigues da Costa Santos et al. IMMUNOLOGIC RESEARCH
- The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?
- (2022) Ancuta Jurj et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A Sweet Warning: Mucin-Type O-Glycans in Cancer
- (2022) Yuhan Zhang et al. Cells
- Collagen hydroxylysine glycosylation: non-conventional substrates for atypical glycosyltransferase enzymes
- (2021) Francesca De Giorgi et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?
- (2021) Silvia Pietrobono et al. Cancers
- New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities
- (2021) Milad Ashrafizadeh et al. BIOMEDICINE & PHARMACOTHERAPY
- GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner
- (2021) Mi So Park et al. CANCER LETTERS
- Anticancer drug resistance: An update and perspective
- (2021) Ruth Nussinov et al. DRUG RESISTANCE UPDATES
- Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in chronic myeloid leukemias
- (2020) Eduardo J. Salustiano et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of α2M
- (2020) Chang Liu et al. Aging-US
- Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance
- (2020) Alex J. Gooding et al. MOLECULAR CANCER RESEARCH
- Differential glycosylation of collagen modulates lung cancer stem cell subsets through β1 integrin‐mediated interactions.
- (2020) Cecilia Gardelli et al. CANCER SCIENCE
- Resistance to paclitaxel induces glycophenotype changes and mesenchymal-to-epithelial transition activation in the human prostate cancer cell line PC-3
- (2020) Leonardo Marques da Fonseca et al. TUMOR BIOLOGY
- Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
- (2020) Natalia Rodrigues Mantuano et al. Journal for ImmunoTherapy of Cancer
- Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial‐mesenchymal transition and modulating SIRT1/β‐catenin signaling pathway in breast cancer
- (2019) Xiaoxia Jin et al. Cancer Medicine
- GALNT3 Maintains the Epithelial State in Trophoblast Stem Cells
- (2019) Deepthi Raghu et al. Cell Reports
- Correction to: LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway
- (2019) Bing Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
- (2019) Andreia Peixoto et al. Frontiers in Oncology
- Polypeptide GalNAc-Ts: from redundancy to specificity
- (2019) Matilde de las Rivas et al. CURRENT OPINION IN STRUCTURAL BIOLOGY
- Insights into new mechanisms and models of cancer stem cell multidrug resistance
- (2019) Y. Garcia-Mayea et al. SEMINARS IN CANCER BIOLOGY
- The multi-factorial nature of clinical multidrug resistance in cancer
- (2019) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications
- (2019) Jonathan W Rick et al. SEMINARS IN ONCOLOGY
- Computer‐aided drug design of small molecule inhibitors of the ERCC1‐XPF protein–protein interaction
- (2019) Francesco Gentile et al. Chemical Biology & Drug Design
- Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey
- (2018) Mengmeng Wang et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Mechanisms of PARP inhibitor sensitivity and resistance
- (2018) Alan D. D’Andrea DNA REPAIR
- Altered expression of different GalNAc-transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer
- (2017) Razan Sheta et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin
- (2017) Phei Er Saw et al. Nanomedicine-Nanotechnology Biology and Medicine
- Drug resistance related to aberrant glycosylation in colorectal cancer
- (2017) Ninon Very et al. Oncotarget
- Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels
- (2017) Lina Song et al. eLife
- The relationship between platinum drug resistance and epithelial–mesenchymal transition
- (2016) Anamaria Brozovic ARCHIVES OF TOXICOLOGY
- Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation
- (2016) Seema Chugh et al. BRITISH JOURNAL OF CANCER
- EMT, cell plasticity and metastasis
- (2016) Christine L. Chaffer et al. CANCER AND METASTASIS REVIEWS
- UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target
- (2016) Samantha Banford et al. CURRENT CANCER DRUG TARGETS
- Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection
- (2016) Zhi Li et al. Oncotarget
- N-acetylgalactosaminyltransferases in cancer
- (2016) Muhammad Ramzan Manwar Hussain et al. Oncotarget
- Glycosylation in Cancer: Interplay between Multidrug Resistance and Epithelial-to-Mesenchymal Transition?
- (2016) Leonardo Marques da Fonseca et al. Frontiers in Oncology
- Editorial: Glycosylation Changes in Cancer: An Innovative Frontier at the Interface of Cancer and Glycobiology
- (2016) Leonardo Freire-de-Lima et al. Frontiers in Oncology
- The cancer glycome: Carbohydrates as mediators of metastasis
- (2015) Siobhan V. Glavey et al. BLOOD REVIEWS
- Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness
- (2015) WAREEPORN WATTANAWONGDON et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Polypeptide N-acetylgalactosaminyltransferase 6 Disrupts Mammary Acinar Morphogenesis through O-glycosylation of Fibronectin
- (2015) Jae-Hyun Park et al. NEOPLASIA
- Sweet and Sour: The Impact of Differential Glycosylation in Cancer Cells Undergoing Epithelial–Mesenchymal Transition
- (2014) Leonardo Freire-de-Lima Frontiers in Oncology
- Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas
- (2013) S Kitada et al. BRITISH JOURNAL OF CANCER
- Increase of O-Glycosylated Oncofetal Fibronectin in High Glucose-Induced Epithelial-Mesenchymal Transition of Cultured Human Epithelial Cells
- (2013) Frederico Alisson-Silva et al. PLoS One
- ST6Gal-I sialyltransferase confers cisplatin resistance in ovarian tumor cells
- (2013) Matthew J Schultz et al. Journal of Ovarian Research
- Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives
- (2012) Nicholas A. Saunders et al. EMBO Molecular Medicine
- Induction of epithelial-mesenchymal transition with O-glycosylated oncofetal fibronectin
- (2012) Yao Ding et al. FEBS LETTERS
- Extra-domain B in Oncofetal Fibronectin Structurally Promotes Fibrillar Head-to-tail Dimerization of Extracellular Matrix Protein
- (2012) André Schiefner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival
- (2011) Z Li et al. BRITISH JOURNAL OF CANCER
- Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process
- (2011) L. Freire-de-Lima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern
- (2010) Özlem Darcansoy Işeri et al. BIOMEDICINE & PHARMACOTHERAPY
- Critical Roles of Mucin 1 Glycosylation by Transactivated PolypeptideN-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis
- (2010) Jae-Hyun Park et al. CANCER RESEARCH
- Fibronectin Increases Survival of Rat Hepatic Stellate Cells - A Novel Profibrogenic Mechanism of Fibronectin
- (2009) Cristina Rodríguez-Juan et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now